aving treatments.
In his new role, Peter will be responsible for overseeing the operational and commercial aspects of Cellular Origins, including manufacturing, supply chain, and customer engagement. His extensive experience in the development and commercialization of novel technologies will be instrumental in driving the company’s growth and expanding its footprint in the cell and gene therapy market.
Peter joins Cellular Origins from Oxford Biomedica, where he held the position of Senior Vice President, Operations, and played a key role in the company’s successful transition from a research and development organization to a fully integrated, commercially focused biopharmaceutical company. Prior to his time at Oxford Biomedica, Peter held various senior roles at GSK, including Director of Biopharmaceutical Process Development, where he led the development and commercialization of cell and gene therapy products.
Peter’s appointment comes at a crucial time for Cellular Origins, as the company continues to advance its proprietary technologies for the scalable manufacture of cell and gene therapies. With the demand for these therapies rapidly increasing, there is a pressing need for innovative and cost-effective manufacturing solutions that can meet the growing patient needs.
“I am thrilled to be joining Cellular Origins at such an exciting time in the company’s development,” said Peter Crossley. “The team at Cellular Origins has already made significant progress in developing scalable automation solutions for cell therapy manufacture, and I am looking forward to leveraging my experience to further accelerate the company’s growth and impact in the cell and gene therapy space.”
Cellular Origins’ CEO, Dr. Dan Gooding, also expressed his enthusiasm for Peter’s appointment, stating, “Peter’s wealth of experience and proven track record in driving operational excellence and commercial growth in the cell and gene therapy space make him an invaluable addition to our leadership team. We are confident that his leadership will play a pivotal role in realizing our vision of making cell and gene therapies more accessible to patients in need.”
With Peter Crossley now on board as COO, Cellular Origins is well-positioned to continue its mission of enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies. The company’s commitment to addressing the challenges in manufacturing and delivering these life-saving treatments remains unwavering, and Peter’s appointment signifies a significant step forward in achieving this goal. As the demand for cell and gene therapies continues to grow, Cellular Origins is poised to make a substantial impact on improving patient access to these innovative treatments.
Source link
